Business context and reporting period
Issuer mismatch: The supplied filing is Broadleaf Capital Partners, Inc.’s Form 10-Q for the quarter ended June 30, 2013—not a filing for Red Cat Holdings, Inc. The summary below reflects the filing text provided. It reports the three- and six-month periods ended June 30, 2013, compared with the same periods in 2012.
Broadleaf describes itself as a diversified investment holding company that sold its Canyon Shadows investment in 2012 and is seeking new opportunities. Its principal active operating business is Pipeline Nutrition USA, Inc., a startup selling sports and nutritional supplements.
Financial results and condition
- Revenue: Six-month sales were $22,673, versus $8,454 a year earlier. Second-quarter sales were $12,296, versus $7,821.
- Profit and margins: Six-month gross profit was $9,370, a gross margin of about 41%; the company reported a net loss of $27,628, compared with net income of $956,886 in the prior-year period. Second-quarter gross profit was $7,677 (about 62% margin), and net loss was $8,979, versus net income of $22,978. The prior-year six-month profit included a $927,318 realized investment gain and debt-forgiveness income.
- Cash flow: Operating activities used $42,144 in cash in the first half, compared with $44,667 in the prior-year period. Investing and financing cash flows were both zero in the current period. Cash fell from $107,627 at year-end to $65,483 at June 30.
- Liquidity: Current assets were $105,821 and current liabilities were $85,080, leaving working capital of $20,741. Total assets were $105,821; stockholders’ equity was $20,741, down from $48,669 at December 31, 2012.
- Debt and obligations: Notes payable totaled $30,383, all classified as current; the filing says two notes were in default. Accrued interest was $17,644, in addition to accounts payable and accrued expenses of $37,053.
- Other: Accumulated deficit was $14,287,864. The filing reports 167,097,874 common shares outstanding as of July 31, 2013.
Material changes versus the prior comparable period
Sales increased as Pipeline Nutrition generated product revenue, while the prior-year comparison included limited residual investment income. General and administrative expense fell to $45,861 for the first half from $105,417, primarily because of lower professional fees. The company shifted from substantial prior-year net income to a first-half loss, principally because the prior-year period included the Canyon Shadows gain and debt forgiveness; the 2013 period had no comparable large one-time gain.
Outlook, risks, contingencies, and unusual items
- Going concern: Management states that there is substantial doubt about the company’s ability to continue as a going concern. Cash is not expected to fund operations for an extended period, and Pipeline Nutrition had not generated positive cash flow. Management identifies potential stock sales, conversion of notes to equity, and acquisitions of profitable businesses as possible funding or growth measures, but gives no assurance they will succeed.
- Operating risks: The company cites limited capital, uncertain demand and profitability, execution risks in developing and marketing products, and the possibility that expansion will require additional cash or equity. Additional share issuance could dilute existing holders.
- Debt and contingencies: Certain debts are in default, though creditors had not pursued collection. The filing retains a $10,383 liability related to older convertible debt despite management’s view that the statute of limitations may have passed. It reports no open or pending legal proceedings.
- Controls: Management says disclosure controls and internal control over financial reporting were effective, but also describes significant deficiencies related to limited experienced personnel, inadequate segregation of duties, and the absence of an audit committee and financial expert. The filing says the auditor did not attest to management’s internal-control assessment.
- Data inconsistency: The financial statements report first-half cost of sales of $13,303, while the MD&A narrative says $11,303 and describes cost of sales as 40% of revenue. The source text does not reconcile this discrepancy.
Important facts for investors to verify
- Confirm the issuer: the filing identifies Broadleaf Capital Partners, Inc., not Red Cat Holdings, Inc.
- Reconcile reported cost of sales and gross margin between the financial statements and MD&A.
- Verify the status, default terms, and potential collection exposure of the $30,383 notes and related accrued interest.
- Assess near-term funding needs, operating cash burn, and whether Pipeline Nutrition can reach positive cash flow.
- Review the going-concern disclosure and the stated internal-control deficiencies, including the absence of auditor attestation.